Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Treatment of bronchiectasis exacerbations in children: which antibiotic?

Bronchiectasis in children that is unrelated to cystic fibrosis is a relatively neglected disease. However, it is an important cause of respiratory morbidity in low-income and middle-income countries (occurring as a sequela of lower respiratory tract infection) as well as in specific populations in high-income countries such as Aboriginal or Maori and Pacific Islander populations.1 Most adult bronchiectasis has its roots in childhood disease, with up to 80% of adult patients reporting chronic symptoms from childhood.